Clinical Utility of a Genomic Predictor Test on the Management of Cardiorenal Complications of Type 2 Diabetes

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2714 participants.

Also called NCT06586203

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose prevention
Phase
Not applicable
Enrolled
  • 2,714 participants (planned count) (from the registry)
Sponsor
Optithera (from the registry)
Registry
  • NCT NCT06586203
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Canada (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06586203. Randomized; double masking; primary purpose prevention. Start 2024-08-23 (actual); primary completion 2027-08-23 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Clinical Utility of a Genomic Predictor Test on the Management of Cardiorenal Complications of Type 2 Diabetes
Acronym
GENOCORDIA
Condition
Diabetes Mellitus, Type 2
Condition
Cardiovascular Diseases
Condition
Diabetic Nephropathy Type 2
Intervention (Device)
Polygenic Risk Score
Lead sponsor
Optithera (class: industry)
Collaborator
Genome Quebec (class: other)
Collaborator
Genome Canada (class: other)
Collaborator
ELNA Medical (class: not stated)

Record details

Record id
cardio:ct-nct06586203
Content hash
bae05092718d7fde7ac3ff40334d60a41ea1ddb5dd7fdca2eb436f55c46fd069